Literature DB >> 32088997

The expression level and diagnostic value of microRNA-22 in HCC patients.

Zhen Zeng1, Jinghui Dong2, Yinyin Li1, Zheng Dong1, Ze Liu1, Jiagan Huang1, Yonggang Wang3, Yunhuan Zhen4, Yinying Lu1.   

Abstract

Background: Involvements of microRNA-22 (miR-22) in cancer have attracted much attention, but its role in diagnosis of hepatocellular carcinoma (HCC) is still largely unknown. Therefore, the aim of this study was to investigate the expression level and the prognostic value of miR-22 in HCC patients.
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to evaluate serum level of miR-22 in 108 HCC patients and 67 healthy controls. The relationship between miR-22 expression level and clinicopathologic characteristics was analysed via chi-square test. Receiver operating characteristic (ROC) curve was built to estimate the diagnostic value of serum miR-22 in HCC.
Results: miR-22 expression was significantly down-regulated in HCC compared to that in healthy controls (p < .05). And the low miR-22 expression was significantly associated with vein invasion (p = .002), TNM stage (p = .013) and high serum levels of AFP (α-fetoprotein), ALT (alanine aminotransferase), AST (aspartate aminotransferase) and ALP (alkaline phosphatase. miR-22 had a high diagnostic value with area under the curve of 0.866 corresponding with a sensitivity of 89.3% and a specificity of 68.9%, respectively.
Conclusion: miR-22 expression was down-regulated in HCC patients. Serum miR-22 might be a novel diagnostic marker in HCC.

Entities:  

Keywords:  MicroRNA-22; diagnosis; hepatocellular carcinoma; qRT-PCR

Mesh:

Substances:

Year:  2020        PMID: 32088997     DOI: 10.1080/21691401.2019.1703723

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  5 in total

1.  Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma.

Authors:  Yujia Fang; Dong Yan; Lixin Wang; Jie Zhang; Qingfang He
Journal:  J Clin Lab Anal       Date:  2022-06-06       Impact factor: 3.124

2.  miRNA-22 Upregulates Mtf1 in Dorsal Horn Neurons and Is Essential for Inflammatory Pain.

Authors:  Ling-Yun Hao; Ming Zhang; Yang Tao; Hengjun Xu; Qiaoqiao Liu; Kehui Yang; Runa Wei; Huimin Zhou; Tong Jin; Xiao-Dan Liu; Zhouya Xue; Wen Shen; Jun-Li Cao; Zhiqiang Pan
Journal:  Oxid Med Cell Longev       Date:  2022-02-10       Impact factor: 6.543

3.  MiR-22 Deficiency Fosters Hepatocellular Carcinoma Development in Fatty Liver.

Authors:  Monika Gjorgjieva; Anne-Sophie Ay; Marta Correia de Sousa; Etienne Delangre; Dobrochna Dolicka; Cyril Sobolewski; Christine Maeder; Margot Fournier; Christine Sempoux; Michelangelo Foti
Journal:  Cells       Date:  2022-09-14       Impact factor: 7.666

Review 4.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

5.  TMEM206 is a potential prognostic marker of hepatocellular carcinoma.

Authors:  Li Zhang; Shi-Yi Liu; Xiao Yang; Yan-Qing Wang; Yan-Xiang Cheng
Journal:  Oncol Lett       Date:  2020-08-28       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.